A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. A lot of organizations like to say publicly that “the client comes first.” ...

Since small businesses can't change the structure of the market, you have to analyze how it affects your firm, identify the negative aspects and change your company's approach to the market to ...

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. This ...

However, the complexity of snake venoms poses a challenge, because toxins — even those of the same family — differ in structure, and a variety of protein inhibitors may be needed for effective ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

That extends the use of the drug in relapsed or refractory disease – for which it has been FDA-approved since 2020 – and makes it the first anti-CD38 competition to Darzalex (daratumumab ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...